confirmed that ω-3 supplementation reduced serum alanine aminotransferase (ALT) levels in NAFLD patients [MD = −9.18, 95% CI (−12.41, −5.96), p < 0.00001], indicating benefits for liver function. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.